Patients with HLAP had higher blood glucose (GLU); on the one hand, more of them had comorbid diabetes mellitus (DM), and on the other hand, they had more severe pancreatic inflammation leading to disruption in the pancreatic endocrine system and reduced insulin secretion, which further elevated GLU. Here, HLA-P is linked to diabetes mellitus.